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Résumé en
anglais
Alzheimer's disease (AD) is the leading cause of dementia. In addition to a decrease
in brain cholinergic activity, AD is also marked by glutamatergic excitotoxicity that
results in neuronal death, characterized clinically by a loss of learning and memory
abilities. The currently available drugs for symptomatic treatment of AD (i.e.
memantine and acetylcholinesterase inhibitors) only temporarily slow down the
natural history of the disease process. Among them, memantine is the only one that
acts as a non-competitive low-affinity modulator of N-methyl-D-aspartate (NMDA)
receptors. Memantine's modulation of NMDA receptors has been reported to prevent
the neuronal necrosis induced by glutamatergic calcium neurotoxicity, but not the
neuronal apoptosis resulting from oxidative stress. This observation calls for new
drug regimen strategies based on memantine combined with molecules having
antioxidant effects, in order to create a multi-target therapy to increase neuronal
protection and prevent AD progression. We wish to highlight that vitamin D is a
secosteroid hormone that is suggested to have neuroprotective effects that include
regulation of neuronal calcium homeostasis, as well as antioxidant, neurotrophic and
anti-inflammatory properties. The combination of memantine plus vitamin D may
provide, in one treatment, enhanced protection against several degenerative
processes linked to AD. Based on the present rationale, a clinical trial testing this
hypothesis is currently in recruitment (AD-IDEA trial; ClinicalTrials.gov identifier:
NCT01409694). This new pharmaceutical composition may provide an effective
solution to the problem of neuronal death and cognitive decline in AD.
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